Their origin and how they transform cholesterol, phospholipids, plasmalogens, polyunsaturated fatty acids, sugars, and proteins into deleterious products. Free Radic
Biol Med 2006, 41:362–387.PubMedCrossRef 10. Mrak RE, Landreth GE: PPARgamma, neuroinflammation, and disease. J Neuroinflammation 2004, 1:5.PubMedCrossRef 11. Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BM, Brennan FM: Suppression see more of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. Rheumatology (Oxford) 2009, 48:32–38.CrossRef 12. Simmonds RE, Foxwell BM: Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:584–590.CrossRef 13. Jin JQ, Li CQ, He LC: Down-regulatory effect of usnic acid on nuclear factor-kappaB-dependent tumor necrosis Momelotinib factor-alpha and inducible nitric oxide synthase expression in lipopolysaccharide-stimulated macrophages RAW 264.7. Phytother Res 2008, 22:1605–1609.PubMedCrossRef 14. Yun KJ, Koh DJ, Kim SH, Park SJ, Ryu JH, Kim DG, Lee JY, Lee KT: Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. J Agric Food Chem
2008, 56:10265–10272.PubMedCrossRef 15. Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M: Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 2001, 37:1570–1578.PubMedCrossRef 16. Jobin C, Morteau O, Han DS, Balfour Sartor R: Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998, 95:537–543.PubMedCrossRef 17. Ritchie SA, Ahiahonu PW, selleck compound Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y,
Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010, 8:13.PubMedCrossRef 18. Ritchie SA, Heath D, Yamazaki Y, Grimmalt B, Tobramycin Kavianpour A, Krenitsky K, Elshoni H, Takemasa I, Miyake M, Sekimoto M, Monden M, Tomonaga T, Matsubara H, Sogawa K, Matsushita K, Nomura F, Goodenowe DB: Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 2010, 10:140.PubMedCrossRef 19. Davies GF, Roesler WJ, Juurlink BH, Harkness TA: Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 2005, 46:1199–1206.PubMedCrossRef 20. Serhan CN: Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.